17
total announcements
543332.BO · 15 min delayed
Epigral Ltd
Epigral Ltd has informed the Exchange about an Investor / Analyst Plant Visit on 03.09.2026 at Dahej, Gujarat, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Epigral Ltd
Epigral Ltd has informed the exchange about a one-on-one meeting with an investor/analyst on August 20, 2026, in Ahmedabad. The meeting's schedule is subject to change due to exigencies. The company's latest earnings and corporate presentations are available on its website.
Epigral Ltd
Epigral Ltd informs about officials participating in EMKAY Confluence 2026 on 12th August, 2026, as per Regulation 30 (LODR) and Para (A) of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Epigral Ltd
Epigral Ltd informs about a one-on-one meeting with investor/analyst VVD Asset Managers on August 3, 2026, in Ahmedabad. The meeting's schedule is subject to change due to exigencies. No unpublished price-sensitive information will be shared.
Epigral Ltd
Epigral Limited submits Transcript of Conference Call discussing Q1 FY27 Results, highlighting a 15% revenue growth and EBITDA margin of 25% despite a challenging operating environment.
Epigral Ltd
Epigral Ltd has published un-audited financial results for the first quarter ended 30.06.2026 in the Financial Express newspaper, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Epigral Ltd
Epigral Ltd has published un-audited financial results for the first quarter ended 30.06.2026 in the Financial Express newspaper, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Epigral Ltd
Epigral Ltd has made available the audio recording of its conference call discussing Q1 FY27 results, as per Regulation 30 of SEBI (LODR) Regulations, 2015.
Epigral Ltd
Epigral Ltd has announced its Q1 FY 27 results, with revenue growing 15% to ₹ 709 Crore, driven by volume growth and improved realization. EBITDA margin stood at 25% and PAT rose by 25% to ₹ 99 Crore. The company has also approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP).
Epigral Ltd
Epigral Ltd, a leading integrated chemical manufacturer, announced its Q1FY27 financial results, with a 25% YoY growth in PAT to ₹ 99 Cr, and a 15% rise in revenue to ₹ 709 Cr. The company also announced plans to deploy ₹600 Cr capex for Epoxy Resin & Formulations and setting up a Multi-Purpose Plant. Epigral's board approved the strategic expansion, which marks the company's forward integration into the advanced materials and specialty chemicals segment.
Epigral Ltd
Epigral Ltd announces establishment of a new manufacturing facility for Epoxy Resin and formulations and Multi-Purpose Plant at its existing facility in Dahej, Gujarat. The facility will have a proposed capacity of 1,25,000 TPA and is expected to be operational by H2 FY2028. The investment required for the project is estimated at Rs. 600 Cr. and will be financed through a mix of debt and internal accruals.
Epigral Ltd
Epigral Ltd announced its unaudited financial results for the first quarter ended June 30, 2026, with a profit before tax of ₹133.18 crore and a profit after tax of ₹99.18 crore. The company's revenue from operations was ₹705.36 crore, and its earnings per share were ₹22.99.
Epigral Ltd
Epigral Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at ₹705.36 crore, a 17.3% increase from the corresponding quarter last year. The company's profit before tax was ₹133.18 crore, with a tax expense of ₹34.00 crore, resulting in a net profit of ₹99.18 crore. The company's earnings per share (EPS) for the quarter was ₹22.99.
Epigral Ltd
Epigral Ltd responds to BSE's clarification on volume movement, stating that the company has made all necessary disclosures and the volume movement is due to market conditions.
Epigral Ltd
Epigral Ltd has informed the Exchange about a Conference Call on Monday, 27th July, 2026 to discuss Q1 FY27 Results.
Epigral Ltd
Epigral Ltd has been asked by the BSE to clarify the reason behind the recent movement in trading volume, with the reply still awaited.
Epigral Ltd
Epigral Ltd has scheduled a board meeting on 27th July 2026 to consider un-audited financial results for the first quarter ended 30th June 2026 and to take on record the limited review report of the statutory auditors.